CONSULTING AGREEMENTConsulting Agreement • March 25th, 2022 • POINT Biopharma Global Inc. • Pharmaceutical preparations • Ontario
This Consulting Agreement (this "Agreement") is entered into as of January 1, 2022 ("Effective Date") for a term ending on December 31, 2022 ("End Date") by and between POINT Biopharma Inc., a corporation duly incorporated under the laws of Delaware ("POINT" or the "Company"), and between Dr. Neil Fleshner, 1510789 Ontario Inc. with a registered office at 610 University Ave. Suite 3-130 Toronto, Ontario ("Consultant") POINT and Consultant are hereinafter collectively referred to as the "Parties" or singularly as the "Party." In consideration of the mutual covenants contained herein, the Parties agree to the following terms and conditions:
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) THE TYPE THAT THE COMPANY TREATS AS PRIVATE OR CONFIDENTIALPOINT Biopharma Global Inc. • March 25th, 2022 • Pharmaceutical preparations
between Point Theranostics Inc. a Delaware Corporation with its registered agent National Registered Agents, Inc. 160 Greentree Drive - Suite 101 Dover, DE 19904 U.S.A. –herinafter called "POINT" - and Scintomics GmbH Lindach 4 82256 FUrstenfeldbruck Germany - hereinafter called "SCI" -
POINT Biopharma USA Inc. Employment AgreementEmployment Agreement • March 25th, 2022 • POINT Biopharma Global Inc. • Pharmaceutical preparations • Indiana
This Agreement (as defined below) sets out the terms and conditions of your employment by the Company and will constitute your employment agreement.
